ࡱ> # !"@=] 7[Dx` G] WF)+ x\lUv8J֢-iԚ`N:q`ӂCC'Qaeb11@AAf'Q̶'ᖙs=-x=~sν hB'?vMZP~˭Sf0`G סi3yUrF`1.BE{bC".BMy+b0.G= O'7^nA?v ӥєҎERgWHCKRz$V*U-a_hilԕS66,Dr_N~U"T s0"n申IʧJq5#q4srsm%nS+JL[i߁_RAB4l0-mldk{µ_Mpǐ|pދٸIc:֡gGui*?tǒ6J[^f}ʵxIC~Ai7)'Ҿ}}+~AiqBqTϟ-0y/eޓx(@w_+ \M0z ƙoݏguCfPz: )=q/56$;:XFkU_juZ|M/Яzn|>g*i`g~oc6ob&w0 of/`x=~ïcx1ux.dB/c2ac:?'2_f[ 1=fi b3 gx=2|.61!? .w1|w0 ax{輀-,bo|~>ubBtrD{,1f},=b,c,VcE{Yi`f-eŎ,VE+ul-#-Sk0[|8Ŵ(ڢlI /FL]èg0[`C<10[uv/UcY?̖=^jEQ=Oneiɖg"lz?f [#}ldn^.̖o'-ZP;>;u d%R?d2x)൯?S(L;pcL}\~6IϒSayY8%OqzW. j@Ŀނ/俟; [׺>%+,?^*c9VeTq#1PƍVeTQIeTʨ*&b* CVeoT7UJDaaqoo94pη䬂KIos%DX0p䬆IӒs3Ź87[r@CVnjy=ι8wYr\8΃7`Ok}ϤSaNhOf7K ּ|n\y?nWa}cH;ƚ{-x㽉txo$ޙּx yk}-o5 >2GH #ּ>g}ʚ?ޞ'ݗ [>}Ϛ? ak^x;IxOZDz7@joP)7/d[7ʿ˿>9Ldʲvh^\4VbofMno{pM u* NFh瘖c*}|9?|uyҿ߭(ζ˲9vO)l:.9QR(=M =Nx҆p$w/z<ro%a:^73Dѣ_rE|qHV6* pFJj\&!э5k8VP,Dt0xn<wmjQ]@z| ׼߫~d }7ރS͡}cX^D=ub]VP]X]1g|΁2Q#Ze?{ (WZd|+Y|O#,q#}^ňax|5:Gq;/a3So/`D}IJ]D:N]/R[2?{5 n_`nc {L6IDPNG  IHDRqzsRGB pHYs+^IDATx^T?`];RD "H/ "XPbD ~AH ( {vaYLfS}z˖-ӧ=X ǨQvɒ%[]X@QLйsؼֲe˿5>ݔfgg.|SRRN<>ς߇u<&r' ) jk۩_~5gΜQ#:j.PBmGٔpI@qETS%jz6aXMճg}&=ڹeS" vj(U3J._Hirrr( E}Դ\L3MiӦK@۷כ1chRCDo;uS@xlj >5kṪҥKkb>TTGn ģZ4+Wׯ_҅C1VXQ|y @@>_S5kqjfffb իϘ1Cgt|^zi> r  @@ܯW^18 @6GMUH‰' @qN3gN:u~@ⱝj/Ar ijvԡJT?C\I6M믇 VJ?7ov%,  `2? /ԫWcǎNNN!@qB6M}ڴicQڛnF{qB7!@ ئz) ]weETطoߓO>ys !@lTC+TD#Goذ=JJ7;|  !5ԾD*mݦ];v< 8h 5j7.C 8֭[O meԨQÜh+99:W_[]w @ n ئ4kXC 'ଦ&%%E?, BYMD2 45& #!@ د<  د!MB@N MS\M  ئ[F "V}a- D/4Uޠ2hV$ D4էKg4@T'@@@S.b = , &va= D45zK @ ]X@CM@mk* _kj~->@@l@ScmSX@!`Fz  D45zK @ ]X@CM@mhjlC@@S.bk5uݻw/~ٳ_͚53t2mڴخO p?~m۶ .Lp,X@ouы n5k֘d:|՚㏫=tЈۏ lT9ܹSbRR$/3j _^o6mU+tEèj]vs3 =ڷo/cƌsɴ4mN,\(0ԎGbmQ峤aÆvgsJ6lP|y٩3 믫)SzAa<5("@p p믿bټS|P7T;;wJSHVZ͞=;A @1Gvz\ 0D;}3Ns$v`԰A8S -d+V8A 2QRB뮻6mڤKw}߼y&R(-[6qHN VhԩS /uչ^Ǐ5I&E9sԩ)JM]xe)0qV@IM*V []Ⱥ5Vנ@sN|رE_|EL'CLWC|zΝ;EP'^$ #}lٲ[t{]D ]Ѥ$}7BXbv@@p7~mGJ@~ A"T߯C- @ j Q[5@1FM \@ZhjV A@@Sc0Ua c0̅ %ࠦ>`-F@@tpDS7o|u9rğ/;D  ?hMMOOAݺu;vXRReܘ1c̹9y.@@pDS? A#F0oc}hH pDSO8aS .R.feeEy  HM-^1Q^~ٺ6"YA@4pDS5v]w޽ۜh^СC۞={F@#c%KԬY,QM7ݤu5:/Vȑ#| @@M0\R%j֒>ԭ[7@]TxI7n;vl*MLLT˵G/¶mۺtb@Ν;%Ė\ǖX @ =eV]Aot`@\FAM8qbƍl!ۺukǏ2@4n6l~m ٳxW^Ї #ӐNtn_PP*TRE-%@&N:ݹsgɧ}ڵy;cƌ}W_}rHMM  pDSƥI&ժUrO'O6oˠn5 ) J %T!4ըQϪU+gϞ `ٲe&͵^c-y͇ 0pDS+WlL_to^{vU0p@@^ 8jV;Ǐ\ SQ|`Q(16mj/_> fhҥKE2dHr4c7))Io>]/Qu6i8hb@"KM^&VPo3gN(1?p@e2|iӦ>}:( ~=+,^XӀIQFor>q,&ojs@!b_5,Ԃ3$@(85Ց߂[O #՚zkR=t  WpJS @ G48Գ>!`ԠH@5\ۜ9s:wVZh/B $=z8qЉW>'O={hjtkk pט~ɗ^zIy+Wb֭A-O>#aIIR7xC-Ԋ+dUwmU7 ,^{+VӧW^@.#TEnx!skFFVJnC)UX`M .\Dd޳2e&@Xf/KC1P(;눦n޼q(=5Ug͚u7:Z233MXɪ#ӆ>>eV(<$I ԡCݺu{7AmSp裏CK.uEBB!jw /ȒzH]ʖa֭[Yռ^߻,P - "IMCc۶mu1FL7N"SIJo&멝&UT⪷j}^d(3~q@QS7 41%߲eKe!RSjckI}#f W,;4eЇ~hb W|o߾3FN6w%uMMGBm۶mmL @ 8}1ݻ͹,;j5op'k+>w<&+Y… K.._Tu/&T=/^|x{l!ja m%63>.ߛnɌjrȑ83 \_~ա+V(_Wbj(ZZ65F b/d댂z 0s.]D y% PTz @ DrHqƱcjiZ&ڋZ! ڑV?}6hР&M5=m$@jb 5H.='9O6N.Cin曝"3úbAՑ59_@Aͷw@.&?~e =mzbRB#`Zc۔JsQLP5X}:uj$ mjzRA+5ٚ|wU0a&+@@ Dn DmȄS:rO:&^SE5&Ba3R]Zը CA6M4V+.HDȄ/\yP[|5\SdIu5.]Ο??|H@p#j6Oա1^zf_~;o6lj*ڸ^ 0pDSsoG^uUA%>׮]@8G4UƱiӦyyh]1>/^C ǎ3 \5[5:zjժرs@@88^o=ĉ5H(f>㖿<>x*SyyzvZjW_}U'oF88Q @ G4G)Q>qİa4HӋtEjq꺢ꇲM\Ub~z]j*G|s@@88?MǭPOC޺uI-nO[5"@8G4U^) tnZjvV۴M6jnٲ%ĽLg&:iԨ^5:yd5aM7is@"N zFsayIzQƞ={<[sd3D@"{yM<&=z[5D 7B~K3:T}7nlWY@(~כϠNZ7i8 @O ~orq lT}ټ}˽ tEjW[.H@?4 oFE29۷oܸqtWW|u[*"BTZ5H @pSz 7(b67{|?<ЫWT|w˗/W n pDSB|߬[z?~n5pB^k5O `;G4U#Ν;K>-Ν۵kWvƌ8g|MmZbÇ駦aUe>e i @N-ŋOOOו]v)GVhRؽ[oUқL8oH*q~4@d%+%f-A]?իW?`9 #G~+WlX.] _|ahgPx+&~?^veE@@ 8^{_~?\Ӌtڝl>iPo}#GL0m۶A YݻA +Ϸ%J|7u֍)Ԃ^@E 㩊ͫ*TLݹs̉iAGk!@ <ڵS'|R4WWڪUѣGoٲK.ޫ.J`+@@`zmNoAj{!H) B|>!@!pJSUK*e 2H@1MM^SSSS" 4,  5)k_&M  DG4uٲe7Tڱc9?GAOHH>}ڵky睂ý 8qHVZy[n_322̽Gd+Ud>S$ 8DMvlWR%:vzbRB#}{/K_{wiO򔔔}Z G 8׶{ӦM ZcF`Gd{Im\F>d@pDS5_Wdvj$ mꄭ+W6.]+j-[։ WQӯ_?u?~\jjzWI@p@״8Qv<۠A'NKM|Mݺufe{IvyYfmϙ !@ dO4|WPZzuMPO7;gΜjP$ 8$՚h׮"(=۷/VUVG޲eK.]ۻw^¡a \/SL(3)e@@T4yUXjO 6$]`҇Nok!7J-p„ =zh,VNVe 錠r@M ~/_~5ה,YhѢ^])yW(,[L=X ǨQvɒ%>1>|XUo@Uom&M222WUZhjjjvvv4hĔmc;+-Q0aS՜էVn5--_ѳ jԼ0~/ /ڵkk˚թqt^;#A8p&4y}4rȋϾ:#| Du;Ucǎ!C˙+VTS];v\fFR+UJT dxQMe~˗7~4sœFvTvj)!.۩QZ~13_u֫Vz~߻woq֬Y^d~%æ*)kϜ9S\wuJ楩yJ DMup/_z믿^a{U8 ]|BtзMUsJGέe˖7m+UWӟ%! @SU.\rC=VCaѵkJ|PjBs}l֭&qg#WY)@.3FyF:N:R(i @#n޼Y7&jrPP7?M[nxN5jWq*w*o|6f͚ .,]|5RJw}IiJ5tyOCx@@pDS{9 en4L i2xW۷|W 6ɕW^yED)osιxʕ+֡E2+V,% oQ{eӶmԩTY*I-^hVqĉÆ (+)nƍl>}:Owy%fRAq/ "9JlT/jZ&P~(WIݰkkq; @ NiV{ҥKjESԅ(Tk0}vs Z @'* [Clr0a1|_n BM\rqVlj:] 8*^r e_z~xݺudwk> @@TijжƍṢ+⩧ھ}{E:!% G &%}&pujjРAݠ$ =s77f{x$7@L ~E[J85T{ZjP|6s Z @$H߯MawGmf}x-\ Ȉ!@p* ojSOՀC11:U _tT5h:|O?j)Suoo۶y$ D#[ouƌ5mt7|s(#FIOOq0Cf@ "Nt_KPk׮k0u>`*v&ٿQR4 @ NQR(AM'-KB+ٳ4h]vUw޽YYYȇ[ @a H߯t޽p vrr{5qܹ`I_# h%ɾ_MM*F+X &PЦ$\!@0lTp(S\w3gΨ_74@@6M @fhj4A@,MS~ZyOm,= @6MSml @JM՚n@6h`/eP6iD{ @!0(!!ak׮p{!@F6M[uV@+S+Ud7 MSǏ_JЭرcI @~ij_{kO򔔔}N:5hb@bm*{ejq wXAu!֮]{!@ ~8/!C;vLgVVM^zujvq ԃ?Բe6o\oPM6}Wuo_| !䈠p_^WZeS}QPS@h֭[ :>3oF@CM5QFzɓՄDCO!@ 8 +v_}UÆ urW^tE:Ѭ%W2#;w@C:m.\M'N6lUPbbqN<'=ڹeos@ 9~*-s#ժ%_VhlܔoߙN+xyrZ4oVzx'KK,PMPnܻ׫Wݴ>\xhS{q;~z%MJM͚7C/+9u=7O,/>>+wyG2mn̞2+iN9*X+7n4FHVǎ{+^Ԡ ;>pZ+MZ^=ܹȑ#-LVz{Q-5^hիkŖ-[L+O@?^r7&''W̏{[ק͞kԨ< ~ 6!O>]xqVϜAh¦ϲԩfϞ=ᕦL2\r.n۶>*+--MZ||VqUeodP[,Lu4uܝKJXĉ=bT*%ަ8iU"^$&/]:u4''˟ ɥKBJgϞNI…J(/{N؛yg}tUII%SR*qBBW$5@Ѣ}Ŋ+^\j|T *Unc:Vwor^]GnVY^||VqA~DCM ⃀ԉA c;!jm~5>LзqW'8 @&`A@S3" @ i&k)jP#  @ Vئ0vB"`,l%a?q/<xdUHim;=::W$gotcߪ =WjrV(qvJg;j^L{S7Xuƴԩa/jO`_Bǣ"Lbs(mCqiƼ_H6!ESYqhj>EmO>򩧿ui>ȊH4zk($>GW&##Ch iεMӉ'tbdm2y͚5+V^ԨFg Ϝsz8ODƣW<;i0vA@BTG~C\WS (_>QQ{JL2eLbZW>z-3?B5ǹs4|sr2$\W}:=&s*Z')) Ur@p*Mկ  \[NcdbکO<Ϗ Lf' 2И@ Lko:И*(D֭i;T s+&>3D;^|%C1Uv<}dfm%p<*$6\5)zK P@!S]۷o{-[&:uR@ŪtŊG֫z6rțo9hj(b(Ɛ٘ @$5էsZxwܡ] z=gΜ…yVژ~MhkÆ Ӷ/]v;InET;w״{ǎۼ%UlAgOα9W6Lre {7̬={ࢋ~y-lOxh6yN/fzgqM< e_'4աv;wyEbխ[WWRSS7oެRD II[funэ[2E 6[۷M CRb@jjNN4lڴի"{5,Ydʕ[V_u-:ttRymaRu(rTΧJSu)HW0F@lRMUlr7WmSi1RnӽRɓeWFz5jn:}mVOO١S;يiJ/ "H DMujD3j޽{#SihZEh{뢿*9x`~#L{N Yk{E]Ym?k0WS[ DloΝ?JDH\N-cMVwXu1{ܠF NuUrvs@ԵS=.VرcC$4Hwk:jgVհu*e 4Q67s@;ʵ"E.]o\jUDlRY3?ׯ_Nvz!R6mZS`` f-MnfΜQU \KW\q&"7Cfޯ=?:'~iSjI|jI^YJ?g{E))EVIՍի%&JY5e˲e?WZ^ ՟4u?!1  NM^>ܵkRJUjU:eч4M545{Y?߮^ ]7h@Jid1+j|ދÛQ+-[h_ d@־|[FSu*Sʐx<;(=9ȃs0s|3&jKEM}k֜p6mRv̨W+uk8+\׫~_g[#h!ECZ{k;RbEm1#N~ \sWSN5*_BL HZ۔>쳮z b7kKPC%Ϝ_@8{@xjoOlvJ'Јޝ/Yos٭[O)NyV}y>Y5755k˖!Y'iӦE Sʀ na5k_ҧO͟c=}oLEee?wN-igN/*9]8?(#++Hl'R"gsy-2KE33''P` yEc7SeQqx@ "+sF^зs#^qKn˖b X$ԫ%nUU9E좞+99 TL5TqS;RD_-lҤӻTr̡cǎ8[ ۥs9$GLrL)U*d"=sIrrauvXѕ%ud&4_"den҃h2/py:Ś7+ҥtE TQK D#}76[>"!]!}=}ZN[PFV9($I@y$ɾߍ7k!y#&k D#}dz7;)U+Vzը2 c !G4uР_:!Z2 uBj)0S xpDS<ԩW@w@ZMvhћnԡ"B$/^\evZ+#ɴK6߽@6pDSmس7zTZJV YhjdPl!+xǹhp%Chj8v;/-KLr@@ I_Wڂ/ { Snyܟ.Ea*b @ G4599F4^5?qnT)et$wA#jd&NޖRt:'vjUK@ 7INpiShQj0oH @9|#\K>|wy˕MܱcGJ}=;@EM@={?7oK/[p1 K @@§w݋)z o?խ[7;h>n@p@5UUM~W.y]AiԜݻw>*\8|Et yʙЕ/u G #s}|k֬;pڵspzqt!~8eAG45Ŋ;vld$$йˬ={[}٬3W6,6fQm.Ao6k5kڶmqFTnzWo޼9'2umry ^vjŋ[nrʷ~ۧgO5knݺ[ȘNoV!vCD6MMKK4hPffI;}24Z U 9y~T45 @x ئӧO?pbw}zOS}?{4&K[tWLڍ⒀mh"GҥO ?rHP).+iz @ rl%K/!;֧vױQrZtꕋ @|MS_~W\jEo?z4$r[I@&`ZpFSS > 9i1@@ MSo63.'~v*3> %R Ko…$Gǂ ly^r8s~={Ԯ]MÜR K:a„ąC'z^BLf/q.oC0H `;wjeD+u5j*=wڹתU^=6L r `?;Oߺ(MMM6R?111%%e}[ngWz}v*MDJNNhق}{[@!NM-Zhffv ={֓vd~)SN3^ja: + C DMugoNNN('f˜1c4))--M'z۩S'z 1Y< x @!9J҆ ڵBSR 6/_^W4_I( ,0IvyY&s q/ X!sHfʕKp(Ê+z!&*N@,wS3%ӧ vjAq/ "U+I  sR`@ I8qD! @@QS̙SN `/xT{  @@Sy @@SH. 4g `4@@Sy @@SH. 4g `xk wU}ْ@@4hYuT45?hrr>m3?<٥Ig9K\x++Z$j,ag?h_-XEjPT6ꉍ S3⢋.*ScGE.QacFTX3&RS TV-A@ aNq Zhk @ 0o޽{={m$촴+j\+~ߨ-ڬY~5nʩvU˘1c5uG=={VNy3g(VwB .w/|iӦ-XuM=ٳG~ 05>jO?T_rVnΟ?_ŋ#㣽 r @NTj[+v֡)ͿӽکnWՔ_BV٤$uwZ^=xСeVVuM=>_ اOh隋/h[/e=j[]uHUwTkjԨҡ s}wV;'ԩ~IcL%SiF>'o}DS#&az=[]Av쥩nW=’Bi5$3VrfR 8WkQquH\]V<)#^u999+, JrRتU+7'us=<~ѣG^_z%ԣ߫g^S%jbذa>ݝwީGT|hEĞU'*ӹܠ@o]kNu!\R%ٟj5ϧ8V |4s5uĺq5>1&3яH;5b--[l͒5_^M6A2׭[׵kWMo=zfZ\f^5s3gΔS0675UԪG5ޙUf7 hQ h+\G4a%YPu'OTRs&gح[Ǐ7nԨQ7Ť/ÇM=]tѫk| 5yGxwWG35>Q~2m۶TnۨY:9bw9ϸf&GXκ~tY6m&7}=Ryϯ ?h,g4Zަ! :z48йsgTR? :)=t#M2䙀Tz vڥ̖-[֮]ӧOvw}sK/C =|ϖÇ[j}hOq6mNzly}3%G… A0^usr=lٲEږzj:^~eOVC5ܟ|m۶[~5juQeff0!zN?-VN5jdu?Y}… }z1}k6%%EڻwYfNiNڦM}Kڵʕ+wTWT21G߼^#qȑ 6T)&YN=b]oСC%)TfnͫOW=Ӻg"Ċ&Y%faB'`} Il<5@"Py5Zkǎk߾_=zHMMLl%=Ʀ/_KV}[S2u$S$]fD6ѭ["c 3J#i&̼A&~=9^z^] ӯcH?>8kJbD!45 +F>IYqryZ^rkLlT&͔)SL;I_|1)ORM'Ը4> p]'?WUEsSB^bm^55O50II oQn+Cxy{?UVn箈@S#^PPPzL#{P}zFXVznӟg}Wi)VbuxjZHJuϜ=C+f(I\WVz鐹 n:^~؉׳f(m-~~KM~OTǵzWs-EyYv5oy.աXv$pW"Onj ٳMI*[&\ ֧Lj0JcgΡhL:d2Z.VʌzԩS_M=Ta+[3gЭmj^k6&MZx׺Wd>ʟ|gȍa&/8Ii/tdj%i^[A֧UZYhWqH($UuW=֗~P;=b>F-U`Z!6 yY6Xz~[sک!ֲ.xq-t=˝ҟvlI|Q$+.9Գ3d>oϷZ`}fȶx͘\li_FM2Y=_}U?˓IpՃz9yfsE"BEOsLjl2eL;wzF9sEQi۶u$N,8AO/Zkq/۬Tc^C,γ[B35nEXQR| hmZ>_ϕ 6Z,Rt͌˝i}6쏹5~K#N).jb}d^= ,ɓXݤz&Nj J.UgR=kOb69hLq޼y\]>[PV>m.YVꭜ505O[OZS͇nIKVǍgƒuVwӠ%>Kl߉ FM-?To-<7ˡ 0pb@dYQj6)%_uU&zZKtݚ)k.֡dR٠nt!O5돤W ܎K&=OP1D(p4dNT5"}7\Oº.*6>3QYjzX \>ծ]dh-=׍>g1">ZӅ<լ'V!ĎPXAm_~v!2u(*4 7*PSjIA2SÄU4婝&J9 LdԻhZ3P_!ՠn)ti`g?Uy睊'4WҒWy( f?zF寞UVk`CMv7!u觌rPHTa`7&@!@< {p$@3@jGr < {p$@3@jGr < {p$@3@jGr ,jqIENDB`n_%:?&7(PNG  IHDRqzsRGB pHYs+_FIDATx^x;: J%D@4"^ċ *E"E "]&.Ą"Ni˶l9;;Γg3|Lsp#  @hHHH5 !@MÑVHHH{HHH+$@$@$@M=@$@$@rPSp     9r8 PSy T9iHH7?4w #bPS/7{yb@LTXHH.vFSk{! B V% 0 j+! B V% 0 j+! B V% 0 j+! B V% 0 j+! B V% 0 j+! B V% 0 j+! B@Ӛ:{?bC2eJƍb˳ H']M]fͰaÜ 811qȑ2Lx~߾}9eHHH@"-j#G ]t*6m۶-Y M+,XŞ$@$@$ 5n(VRř8͛' 4($$dȐ!r#,C$@$@Т" *_ޙ'n-Zo,C$@$@ʲ%?駟V^]ɘ7nJqVtttFFvVX~Ǿm]-}bdy[-O6[j͛~9$ P@Ϟ,ֲ5UqMX_ZqG2+ pz!*#M PS}]^Wi MB'HH%@Mu5 bT2 yLiH|A㾠nǎ磵o 3}Fxg}v_v6O{$@$@^"@Mh^HH@GQu7\IOg__M$@zBOy**- PS! =j x5Ky  jO.o?j^ 8C %)(YswI^HH@j$4m2e$4C$@^$@M"l'.~TŋS,! jB?Բ /].ЖgHH8yR%k֌W |WRYU xL1BI^ FFbܐdfHHT'@MUMGKGLR?lΝa x5k]PVvիKo?.[ $@$@"@MiׯPZyYT1  jP|e^{=穈ҥm@$@$-Tov:QQڇC\-ܳD$@$ ToPr6C"#X  UPSU*hff3cGq$ B*d#[ξei&,YV9  I@J53uii&|Vdv^HHJC)PUlI^~ڵUs\FHHJG(Y ee9#3Gy2 G[+V zQ&qiUXiHJũ1j{0UMĴM$@zƏg PS^wpFU=&=jU1*z`ѿ)~VstHTXNn'lь+ PSn-ވO5G_IA cǗ<1 H|myjj*(,gjH0uzf֡m y tHtC gO55~۷o7oNNN." ),L$@$5ՅCSڧsnFV|b8wɔe̥99U*[v#>JRS]{% 'PS"To žIK9%,7SS]{% '8KDΐzu}/K$@$`5_cw%eU ~ .PScK=yX>jx4 肀4Mtq@|CD>=<227$@$@Vi*z@ƍE ǽuEKr# -joА)]ZpBx& $45;;)\$`P3:٢9`$@Z# MS6k 8d ^ DaÆGyDf{;>W/2?FgUCh|/ xZe˖x &&&,,b8pxxxNVZ }!_/$2"ΥYfVw쌎H4E@M_6mqdTzu) 0dC?7”ߡbK` " /PES?x L2qh@{x>xo/W3ވn,aa6&FF^~oIH@T /˗/M@SJs#8rCW^{l򫯾µPw͙GXJSWPJƩzFJ$)hjZZDSK.ݪU+ݷo^[hcg֬Y6Al۶mɒ%hHb8nkUo̘1 &`G^}UM3QQ|z2$r^Hn!5k.k׮x]nͪ7o8fnHHȐ!C[Y֎=Ν; X/S;N.Ycg$@'&";~}xUsi޳=ќֺuk]+-_(pIWYUd嗢pLF.z^HTTًB v4iW<@/Є6lFGGۄq\3R6+ S1w|M}mpŴp H RgΜ /~O>m~ݻXҐR1Fq [644T4p/r'NիWﭷիx;p@HT ?rhP@LQNےeY׮ s ;ޚsnjG12  ß- uN};wl~cǚ@Z)OGcގ%k׮(W4BܶA'hK r[rr* 虀* `k֬6mZ coڵ͚5[~}ӦMmrŸ$EW'I!}Ǖm۶mĉ:n8Zʖ tq[V\ېyꓪEIJ@M,4!ڵC,R춵4>><@>Ő~xj+"ʋ"0.UPA)x8κhxnNի;\HH$%ϟr{צMć*)\P7oouWsC;X`Ϭ%Y7 蕀/()B8[E|t+!DV*ȭyKMlw ɑyOXHJ@_sXe˖հ>l¢^چ-sqFkP5dp. +֖7j(]IQu똒?~GKPiz58%5i,aSHOMU6͒ Gǚ8}ҥ%K,Z˒G~ż<ڻɐa⼷945bj{<H@%Nj*cCB-[` Ν;+Y4^U@0 Ϝn)t P]S\g7nOELi+i5*# PKS-Z|AqF M iF{>|xʕ}3   5pt/zaÆjxOj01ڔiH@/TԥK^x?l۶^@1$&<)%%f`UMyՈ,3 8A@M]l}7n8'`xcc +Zi{ۆrjv *;v8qoc=$xW_jw_Xl~%^⭱1> Z Do VRy% ґ_f#NU$ sqb[ P*o!$@$p*_3g8FO7]l"C/9~=z[B$>U4}wx,z5xݱ4 Vٕd& B V# %c!F1 =h͹4YYYVT\޽{~>; L|< }񅨾#jM2N~ k׮9\rԩCp!ڇ~:n[[ ;޶Q:6TI$;#0@ffD#E{\|b4?qx\92B)(%*%srmFDwٳ-,kT-4B$@@Ϟ,ک•k׮^ J"h*vgZ,_cbjrXnJ"v*ZXW^Yd 㱫FX*"xċ;rtse?7 _2krEۄdOv=w0%5i,v%ExDF*ֆCGa}JS$@ d;UMţS,H6nܨJ^DZ^ѣV FϰXӧo-$.@ ujSS%&M Nj~s׿XU$rb99?G "}j;5888&&cǎF;CTua^/49۩I|N[^^իW/^)A>LbrMg0gY^ou+sUiH%S]@ NB-Xv*266 lMLL`^ZXy47nXps=]d Aڌ^ 'RSjb +'iHcj6^?pRS1F )7n/¨G}t>{@PPfV.ע|T.*Wv6mלpTO-H$@5o} #F:td2!/lrDO r1сMylQy$ Jdjoݭ[)-|C>}:uJh̔W@$545)) 3d,4i8ҩS'9|p*U;k, Hئucg$@" MSgΜ)b@v֣Gbȑ#z-t7lPIuV_6_FIhi͛?~ٴi8R\VZ={kƚz@A~W#Ο/ز4'Oz煻XFh*^Vf *l1 cϟo/ÇO6SKSEJa*W6왛Hɴyi`|jC@'I Ka$''T!~%½{ ' A0` ,PZgܹSs=poZdIjPMM{OtqI₅Zlx 5?Ǯii7{95sħXcGaDMA3$@>$ }" dx@ctw܁IJӧOm۶yA 2DU[5g~\d| =仴 u<|$o)gnݖ+y fO_5qr掝NX3k|(u&0F *޾Kb'55uhqz u߾}x֭(sr#±⺫Wdy ?"T :O?^ret B[5܄W hPMtZW q94}YΝ;qթ~ j6]DSݎajx" h6I5ڵbnkɓ'W~ĉ:u~ t;x=wJ:랢ǭmKj 'М:I sLU~otsi󉦎|#޶ݻq^tHiNj1JN;VLA ξ9$nݺ6lԨ8',%!*V;H@М*)*}5״iSqD<{xk>M6NR.-М:T  ( 8aboo&8OYU]  ?'9M9r$"S &XEk׆ Mr/W WEX6cPa HK#f~?cvѣbYP-|g!ȹt/KpK4['c H! |bFHprF51K.5odQ"[;>T됡8+4hi.`=}{$P,'5Us}}5(eˋu֥s8cSP 017k"t)i]J2$@Tie˖X~\L2H@xݘFMo%.J(AA}BB@b q~ 79&eJsA ]"i*V{kԨM$@$@$ MSwQ$$48 !~ܙLo}ETnvOĨ`kkX&I޷*\O!p1J_g賌h=={MFFFF(×J 4X̛s2X)3Ө[;ߎQFhcTǹ4U_NzMM^|,?#z>OGBi65jߪv!72 TLVvEԇ:EFܒY&M:yshBSWX1gΜ͛7cT\!VTՈtY .5a,}att`LM-DoX1 ##ujq#JhDTSifdd@;{UV!d_ݽ{\Yi\H@ QQAJbsEPall&@y!6ˠ?) 54˗BMm_lٓO>   PESs=wQa+WP2Ϋ=6_6cL&+S󏰯UvС3g 0:%5(l ;ii ~UNo&(.+`G6Â!%,wn^@N>ݜo$8ҭ[oF# >l˖{F,\}!ժaE{:>ʹggIaHH-GyyG7~ʕ-^⛜<0S;YmۊF]Y8`++VTP{]߈e  ~(~}Gn({<,׭Km*_( MN?=Li햸AJwW񐀓SUTO>}jժ摜={J*8g)tj,#4.}!сc T1ZS{}F23YYEsl6&^zժ/:RB`l_K+gkTUħG'O#q*:9;Zɷ4!ᒅ\)xXJ}M :zTY\T?*W6tiOwkWt/5ULN6ץV,_cSgb^* *ؙٟ?ԯo#-8A|:-]*-ZpMkiY'{E`̔u\gp#(9:g33 ޙΐo_=,ް1Z`wPl(~`w{ !hz8u|0%`oz tI:N-QDzzFjƹ}v`+Sj\V,jj4XIMUeVDf̘af̙RF>Gq7|f͚ +sCI#$@$@$[h*y$m$@$@!VPOIŃRٳn޼9^u Ȣ[x[d +HHD@[M`4rDAV|ɩzXHHH@N>RJСYH`.&/O)ḱWm2g6q˸WVf·o{cZQQQ;v1cvp~Tx("v *$$|QeNon BC#+U;4<1%ݚg¢Uoy…yy7{s>00D,LMٙ}=#?^ř\]N̼91*, 1^]ˉT0ݿ$਩~QMpRTé^zΝqݻX~cg͞/l,ךMsvZ GKQoF)oky8HNWJoo]v*d՛ZTꑚ,@jjzJ$\z\ի JX;S&ךw(U*R% ߳٦G-~ɹljp~!>]%x-_j]a &'5U%ok  HTdV9n3ȗ^zIY <HH<' MS?c>Ʀ[n-Z{5kV\ymyHHHm781&&ƍ"uo32nY`A\%//o?v֭[۵k'1DZK.uRt^b'UsIH@̡9MX_eIH K@"/$Ϲsb8.C$@$@jМ"ɓ'^:!!!22SNxh_Z5jM  p=Pll,F"C۶mǍV?ƍ333׭[ףG׽xbʕ(]g  N@-Mzqׯ_uq@v;v;3JnGejDn}n$@$@$h*20<#hMڌ裏/Q4iUE{׽y D@M!U4UIv߻wozޏW$  6 iذzQ2 x*D$Ϸi̙u$@$@$ *:|Ν;#F`H +WNꫯbK."Y7   ikc7u T^\?U=L$@: Su! 'T!K$@$@~J@*kYୟ"$@$@$`4M%_  08h*2Blذ 茀Ze˖x!%!7ñ*Ut *ui6mB|fp HH T>\ո & AX R/_,ي1{RJJJʹs a *|SLT,ڪU+ݷo^[hcg֬YA0IH B@M븉DZ~xݵkx۵kW[ & A |Ǐ۷om۶buUt 1$ 0U4Utb5_~;M4+~h6 o a *ڳgO۽{w܁;SZj%WOR a *ϋSmرoCCC-7$ 1U4֬Y3mڴ vFvPf͚_iӦ:HH H@ښ~͎kuy P$W0 -Eӑᡇh۶qDFn$@$@$3j"=SO=uEk^%JXx1V;('$@$Aź4Xզ=PS.[';M U;z(uذa"+W8  *:o<D ~ׯ}N>_a-UO}$@$@$%hw}'bTT ^6mB$@$@PESSVj`ʕ7nwO$@$@Z"b挈̙3={VZD -q/$@$@$)U4~͘1AeT|  U4W^"I&=:-- .\x7'L >Rh   O H[?‘:l޼ٞwmڴٹs;cIK$@$C>^?u 6u]P;! K޸qHF#ԥKYfZ|yÓ'  P׿8׿ޒ wm۶7ncHHHTcǎ'00^HHL@ME$ ^#  _PES[FRN-ZlJyyy.E8eʔƍ#^Ǐ<ONNvr,L$@$@PeRDD:lILL\dG}?G,xn)FڵK1JPb 0,_Qmۄ0d2 ,qfG%uiӦaʕ+'n\  p*}:a^^Y{uРA!!!C *-gffU6l<HH\%fggXf}[k-۽{,f͚˗/CY!(!ʂIHHٺu+1[n#Glڴ`> &YSCCCڷoI8I&?SP=|$ ک*Dt ]W_}ղe˅ :_ⱨu`RK APªUT}cI  p@ٖ\WX{YG_X 2TJ֭2 o||<5ιsb_~8n3$~%>6l: HHHC4Uɱ OʾK9Ѻ@dGB~d/-0`qq=DIHH@ isi1S᫽nqҥ͛qS8FI! ]\͍q:˔n$@$@*f}#{Ǎ+B$@$@$ j>JBC4{le83 x|M߼ h5Uk5BHH4MurTEU&  [i* PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP PS ~0|  iP hTSLҸq㰰0bJr|YHH\%XXX9jOLL\dU3|{uf/O R;4' Gs?{X5NݶmL&b8n3WKHHH=yH 2dV9nijHHHX} [n-Z{%$@$@$=OqQmtttFFuŖ߾}᫾Sݻx 螀S5Ǩ֚k]mŖ9rҥKwt^`$@$jm I~ݻx dy~I$@$} 7;;[[M:>b^HH 45蓒 mժ*qAa x4uС¬YW 8abo-}" 1 hNS1Rdιsb_~8n\-ojf$@$@^ 9ME̓'O^zuBBBdddN-[_Z3彀  08Ou>.]ԼyTg ;Ssi2$@$`X: KNN۷ȭύHHC@}L4 7N; iٳG$@$@Z#5HHj*  C*# 5 !@MÑVHHH{HHH+$@$@$@M=@$@$@re_9YswLҁaaR,gdDKq#W3b"Co.qo=q//5[*&#rnfN~AAj_̼070 o67 ; 6J?}2|/;Z菤G /ORR=~]~G&u8tsf=g5X{g u)5?m}e/ɪU+ԹbQSEr:}.'`~}{m޼5[XX臵LIIAͺ|PV;}we)5?,FZ5FwLjhHH"@Mu  @"b  p5)L,D$@$@HHH)T0 KZ,"   PSB$@$@$P,jjXHH"@Mu  @XD.8w\HHHr\>O@J*EDD﮹EIN/^Cy}阘RJvF"Xfdd\zZj^(jr$@$@%_V-# 2jr$@$@%@MYSLiܸqXX^/Ӵfl͞=aH?~|˗G=bd`):s+`8`E\u=0O8!b4Z-plr…ArB'>}H#WaZx>\D z,]ѣGx)߬G҅oڴI*{X5m4_6~%G-_lݺU 0Lxoqܿ-?KK&={ǏoԽ{wn"E,]:rZ^^=+"0uhPnc]"N:0[S6ޱcپ}{hhhɒ%۷o{*G b.Z\VD8UT};wV)aP/MeРA]tAڵkVT~] ?C7@WHrĪEo%X=-6kL|mTP65UClDh܈kJzDCexrn6Ë/1b6mpk]Mʷnnc^׍}ژGHr*::ZĊ9\VЀ;y$}y/iE 5R|"LG?h,X>mĨt{,X4o?Cg5+q*K؁T+ׅLhd{ݿ\fM]\㏣G!+u)M _-2 yU66l(À+={Dmbb+淴OaΥ&=뫴 hÐ#U ~}Dpп{btl`mc=fA75krHrTJI hRGiزpP;XI޼tb #1~Bnjc.nUjP%f1FڴtS~w܁ȱk[7HxHH!1JP9$@$@$`MʻHHH+$@$@$@M=@$@$@rPSp     9r8 PSy T9iHHHHH@jB$@$@T$@$@$ 5UGZ!  j* x믿Z}2^ ҥK{p|ѣGW\9,,,&&k׮JymF&&&/_"""W޷oߝ;w:@eY&Gyd̙gYܙ9.f#$;X~w-x_-Vw(*9'|Rbb Z&=U>RǎksXS*U~z[kƽCiB+jO{KkM#:tؼy +Y\q/dhKaj|Jw_ff&Z6驇tԩ#FpU[.\hӦ͉'%mѢy8jo`߯ iJ.W\Q.m6MFnΞ=+ A&|gb^8v~ٳG("iӦ|؞<۷vힷ[wf9 yGK9k.q͍76id„ 8Ɋf1}1 (_Cs߀AR˗]lSEtrusJ1gl"5IA&C2eyݹsbelzqݴitEHcBs5zk6K5k1 ֭[36l(l9kǁ3 PS\;/ʗ;{^#84Xq6%Dy Z;.맔Ea $oNJ$ʋk׮q)Ec=MPٓy4[q {aBjaguUS]Y{gO[v9,(?{ʵ;gi5U˵Clh*Q!dC ėS/,wiWa)txbX,4)z)8a @ 8,+C7xm94h 5o-BϞo),[t`B7y%Lt\-롷׬=P;Јk֬Y'ǥO:76@0SIzW+W޽[}饗PNFZaṩ88f J?D*SRRqt}ϟ?/@G#J+ 4oܸ_֮y\iab{>;59s@AS9$>r/^m ] l@t1V7~jl,5?LTeMlňY{w'zXNj~~1K|`_Ľ$7{6yFp~"(u߱cGߨQr>5$$os5--dq|0._Cy+?o;p i b(SJ TFs"q)4l6m$oQLRjTR"Y`jjh/_\Tnmۊ#k֬q-O9h; C1tb&+U6Zli)1/F˖-SDYU"r2\̠7JI?PM@ 9TI|DaĆPdI\ݼAK5զh1 xAa0]Xz+M=:(Wk֦W࡯01NH7tLR!m.%,6Sm^޽adIM{ %>kHӧO2R{*Ԝr#bƁ0I1%c>m1֬Y3a=|cR"8M1W䀴Ae Ӧzyèh!ͳcyBT` (_[J ݒA)߼hDړU;4ׁ,)p]hFbc=yk致9(..NT`hs+z^n`p;荷8m{מ2{u/^Zj,.!|a E zv 704†o^r.xEjZVVBmnH Q?CE>DhYK׬{7F9 bNxX`sCEJdl) 6o*E p7{?4yHH\#4bi  G{HHH+$@$@$@M=@$@$@rPSp     9r8 PSy T9iHHHHH@jB$@$@T$@$@$ 5UGZ!  uGIENDB`n) " SyVn)PNG  IHDRdC)7sRGB pHYs :)eIDATx^| U]sC{2 b $8 OESi@GV@'2+@HBHHHnro;g߮ Av~{պsNծ]9C&8s$JƈLyĈMa"qn8\®lB Ĭ,%\tT-@(%4dZ%9y]%)TʮsD#$+"Ə> siVqK!H6;HY_ŭ1^ kIgXTJ ݚjYeäldE-)hH;w:ҕ UQs$fq)䒓gԥԹ%,ɺw!! I`FxX}Dg̈́(Ce"np+}W莞pKKz!;}٧^q(!p,&s>6$k^nZ#̈́E@2p"[Bob Dc*RxnG q!7@[#@ 7ǻYxqLؤW~ý9'29]%DUxϧ9N"!lI|8h]UW({;k0Tq@Xh։%xV߇ !Լe+Je Vd`5<<M6/sQ&+$ IRrsI{]Ttl. -%N*38&4wא4)JQrM32 5Wgǻhֻx֛n|(@ Jc0ᘽfՃ!ƌgdp ]6ޛ @߫g‚Btу͞G0T9 p Pv9vTHeak ijEkR"{]V:u@]4@ňerRutjx,PC$jdmDLB`V@qAE.ڄ.[}Ex*k\y?As,8e0C$)#K.88xxO-rM޵ג-jʼn8uxL-{ I 5gk X&P&AJخd/dRJ5WA٬EZ#lKУatPxW Yzǃ,1hٳgo(} bCp% p•mmm9cd+Y? @] ѪpVE0L0¡:)v:qqv3$3-_uLGk`\0X[[p9IDhQLWc[Y"@jy"HgS`8ލ',w=|Nk.@ctL `ba.M8`UWW7 o CA(Iu@ѭ Iಝ l:!1-VJ"\PW.XR4D$.9P.[d'5ys,it$Rh2khFm}֍z +Qʜm-<*T REiz2g=C8R@A0چ߬CJR#ddddppphhhtttll ZZZV\ r* :\T*˖-;ڄC4Bqphk\%g\ovQE$G %&>n }\y~HP @#cwYJ-1NxH&pzɁ-\\iD7u{&D!CXf2=,XaE +y5VGmv{ >Dt'ge289r$pB΍sA`lG-ZJ~) Ѿs5a1"-=aA7 - Ph\nۮ~oTVTZ#IyXp]1͏8x&6aaAXt W,Px}ZAJ3dD }Bñp; zlݱz|[I #hÌ$"_&YcJZY1fز8'4f yZ| .QR aE5|",)@6E3p\. 0YYPhXW!Kj|dYN,C#v'NXXxƲGPxdӦuli`X60ɋuER2$P'$<(@ˢB @CTd7Lv͠O/^cxOK/2T.Q5ԴH[ 2(.*_ogV:3/{4ф\ĺtdgȒ܃^UzP 5v'0w rf0p! 2HXh3L&b*PmK5&ʍmf@-oiĔó5N' x⩧vzg[njoGLt4Zli}usYb?uh8LA6X8fy۶mGN? /6`؉X ٽ{f߶t޸i? sQbPsny!q$;2m{ 9b?K REYcQ @e&a Evm%5ʊWҋO!nq:2B/Wq7I%j_I( /knl/{-rm.%,p\cYͣ~&'-\:2?榖=P :0Cb`6RKYAyJ#Q%AѲ ]&& lbjJd9dBnP/%RA P'j ZKlA9'ug ,xS-,H)wز-űo߿u^k{&,_u23دϽr>;j!y)W9 E4pm], lo$9$YbbȘ~ Sd A,Y gW4(s! w&0L6547M51N2gn,X)woz4V(5}̥(%;XCuTY.ywg 0\AemUʮϷ1$"xd\CvmH (k׀PBH֟ phsJf$c2PwT,/Z B6ԨRYEA+V* gXn*@nR(ݪPS>zW y{ak/X_9^T#I̗Hy.X2 JGͬb \bZqִ51PFrY2'i ES'@_`-uБb T9h3 ;˵# f7 \;D*4bF,X֭]IgFSE˃1 MTX.C<̿޽;9s.R7cDӾ)S(?hٷOJsMNZNNpq+,32-hpdxě)p|DRN%4Z)DΉʞKۇJEKf #VE"Ԟ>b#.bA-kr{n[/Ϭ!s%kp ,0Yx{a9>޴>PYvB" ʎRPC)?rmJ9g;ڎ׳Xb:>Zx2,hPv wV Ŋ9cj1gq.XIV}j%ՆXm5E~kEEhE@YS2ɸ4˒z1BH0gMk;KOS=mg2rYG(yy!`c:k‚h_YwV0<9 :CLVIw綇:6cNz?r0;"\r:ԇ"pyӪGID CBQ!"(n,tz~:6a)JhIt F ji2{j}Sn7+,*DA( `Cm|aHi~zP,A]˱ed kw Oִ)_qgi2}S>)rL1]pdT1e e] e!"$A/[|: ly}I%A, [={XF3.:- Ea@G$Nx*A?oxdHXlD ~B^~g΂Gr2 t} $Ÿ',VMʩх3a 39b)ㅵqaP{D)Bnx+˱xXHe3VmӼpaGG:C cH~QAlG?SV>9j(`uuȦrSQw\b /ļIDZ8:ų0<%㤯ommۯ))E$-=QȐ [V J͏jW8ZA+EgNx+ M$=!E;*,k~ѕJkGH'W̭ xwp` ZϹJ<ބ ++ 7v#J*V^&K!)^OAMϱ"eЄX|B/ {'M>ߢ!?& +/EM' n˓ x~İ*8{8Y~ +憆lަTA4[eUҐU,TBwQl^h@N D^YJMFBC5B;Ԩ%4]My<ږ2gؠT.nm˶!LV'ˎ,+%AQ^QI[?L$ 7>$Fl^! 3||ҽp")U\/".7IF!oU1'AR \;Tlal F7&, yLjv@4-xmV^GsmB] TUha+{a! b>>Rnxp,Y[+ Rr+ȗ@T E5M6xtd F,(aG Ȼ>PR9Q,jpn,T+t5TH]aUHGi *"-$3ɢR*R62d3 LxOŋxOe<>ֿZ'4ʦ )@4SY#lT $rT1IEld ?Hb죧Ė/M(lQX\I.22%YB 2;_qCP"Dl|*$51ڼg8Rj0 [7/wowLA)Q)9tp ԁͲ0`q/>{ 7{5ٸ-篻ipx(oꛞx=?Ŏd,z/~97gLpǟZ/Kg6/TE[zg}ێo֪P8 'b7⟞8uROoS}嗿{mm'~Nj?`{3λ Mw˖tv`?$1Ikzp!.^p庵@믿g:p38#{ч/YlUtu2{DŽD¤¼|/f29  h~fk;㒋ϛp~I qڳ}nd]x|Dnmx |%_-D"Gҹɳ%ILؤ)V8iDMhuqhp*v.sg\k{ﯻ*⫇G E[z4/\ݽ]bÜοcV=ݹ\龧EDlw d>PY''-[Uð3.C C!M+*9{Sb< `_ Dȃ #_ÇC |ewu\ F@׿>}zmRփСbO/K:>J9fu"!-Ƅ?3K4a:;;95M ,474!,Y2?{ᬬ""/kX͕`1bd{b,gKJl/C,>0f1\  G+WLF@Ry ɀD=5_2 Jc:!͓\ 4%%(<%a$H{kD^>Oerɪ0X+BX[k8RDz?Vזju}|/ 2>Ua+~?/A˄=IAy2 )6DumY03 Yoa/ƪ'.V$1BH݈7x;qcWW.@ތ2W9m"U{|9aT3'ug"}d "]2YlD$R4KVs,rjȢ@F9=B݅n T5E+exVCY8u0#IC P3k(.0Qd9 8#G#h4SHpd7d1Kd@q-N8) 󗾄|o_~E޹g_GuIdhvl6gV՟/Z:@C=ŗo=T_M=l _=;0co PV -477^ƛn;w /lwٻ=}Ŏ;wuikoxᇦN^w?e),iX7u?qG"Ã7ZiXnx~=`xx)?n}xd:z~֡Y?'TIer4e9kɎ(f׾{Ƕ}&_5TҺm2e҇69i?33_IK72m\ɑԈ.XC|UݩΏ55 ΫGz4д}NY@)>]QZrW^W6Ƙֲ(DV9mu[c Ap=#A! 7ڛ_w%cƹ u)+Vg}'TuLm{tKp}~ ֪ -[u" Ki\?nÁMn\8\@i*DÊU/] l 7|XXiT1φ~½b )'E! (K!WIH}M&48q@bE.ϟ;wO? ]=s̕g̚1cH?z'c766.xPSA)}XsO`0 0AA 3f3@T5Q ʚ;db9ʚ;4KdKdiO 0}pp"pp=pp"p#p4pk5pE<4dddd<v 0p/ <4BdBd< 0pv0___PPT10 6___PPT9{?  %X  /   0` 4f` Ϙ``0`0ff` PWP0ff` :ff` #6gff` #60`ff` KKKff` ڻRff` `ff` ϟ0g0ff` f>?" dd!z?" ddR  n"   I n?" dd@   @@``PR  n  I ` p:  >  %P(  P~ $P 0S"?F+` !P s *":"N P HˇCˇC"" 4# 2TEMPLATE DESIGN 2008 www.PosterPresentations.com:300 A2FFnnII P TPˇCˇC "_AE  T Click to edit Master title style! ! P N #" `:"  g-Click to edit Master text styles Second level !  .l P 6g "Fp#`  P s *"""` "P s *"#4"` #P s *"k5E"`B %P s *D)"+F+H P 0ޚ ? #6gffD<___PPT10..j{[n Custom Designr   0` 4f` Ϙ``0`0ff` PWP0ff` :ff` #6gff` #60`ff` KKKff` ڻRff` `ff` ϟ0g0ff` f>?" dd!z?" ddR  n"   I n?" dd@   @@``PR  n  I ` p:  >   T(  f  0"F+f  0":"~  0fS"?+FOK  HˇCˇC"" :# /POSTER TEMPLATE BY: www.PosterPresentations.com:000 A2FFnnII  TˇCˇC "_AE  T Click to edit Master title style! !  N #" `:"  g-Click to edit Master text styles Second level !  .l  6g "Fp#f   0"4"f   0"k5E"H  0ޚ ? #6gffD<___PPT10..j{[n 1_Custom Design   0` 4f` Ϙ``0`0ff` PWP0ff` :ff` #6gff` #60`ff` KKKff` ڻRff` `ff` ϟ0g0ff` f>?" dd!z?" ddR  n"   I n?" dd@   @@``PR  n  I ` p:  > 0 x(  f  0"F+f  0"E"~  0fS"?+FOK  H(ˇCˇC"" :# /POSTER TEMPLATE BY: www.PosterPresentations.com:000 A2FFnnII  T\(ˇCˇC "_AE  T Click to edit Master title style! !  N( #" `AE"  g-Click to edit Master text styles Second level !  .l  6g "Fp#H  0ޚ ? #6gffD<___PPT10..j{[n 2_Custom Design 0 zrL (  L L 0! P   ( P*   L 0TT"`k5E  Conclusions& 0( 2  %% g HH3333"`k5E gyWe conclude that patients undergoing RIC allo-HSCT using ATG as part of the preparative regimen are at higher risk for EBV reactivation. However, this did not translate into a significant impact on outcome since monitoring of EBV viral load using quantitative PCR and early systematic preemptive rituximab therapy allowed for significantly reducing the risk of EBV-related LPD.Hz@'`P ` @d(    H %%%^ i Hԅ3333"`k5E Previous studies reported an EBV reactivation incidence ranging between 0.6 and 26%, even higher in the context of T-cell depletion and with mortality rates following development of an EBV-related LPD between 50 and 80%. (1,2) The current study reports a cumulative incidence of EBV reactivation of 21% (95% CI, 15-28%), but none of the patient experienced EBV-related LPD signs or mortality. In this series, the absence of EBV-related severe complications is likely due to both strict policy of EBV monitoring during first months after allo-HSCT and the systematic use of pre-emptive rituximab in those patients experiencing a viral load >1000 copies/105 cells. In the current series, the response rate to pre-emptive rituximab appeared to be similar to that previously reported in the literature(3), with efficient and sustained control of EBV viral load in the great majority of cases. In our series, the incidence of EBV reactivation in the subgroup of patients receiving ATG was 24% as compared to 5% in the remaining patients and showed that the use of ATG as part of the preparative regimen was the most significant risk factor for EBV reactivation. This data supports the well established role of ATG for in-vivo partial T cell depletion.(4)<T`)` O`@g`D `  h @ ` $$M(`(,,,@,U0`04@4~8`8s<@<<<<@<Z`@xT )  O 7  ,  }  E U ~  P  Z $ j BlTT"`: Patients and methods&0( 2%% l Z_3333?3"` ! }In all, 175 consecutive patients who received a RIC allo-HSCT for hematological malignancies in a single institution (University Hospital of Nantes) between January 2005 and June 2009 were included in this retrospective study. Patients receiving RIC allo-HSCT using unrelated cord blood cells were excluded from this analysis. During the first six months after allo-HSCT and in patients treated for GVHD, all patients were weekly DNA-PCR screened in the peripheral blood for EBV reactivation and were clinically monitored for clinical features attributable to EBV. EBV viremia was defined as 1000 copies of EBV DNA/105 cells. EBV LPD was defined as biopsy or autopsy proven post-transplantation lymphoma, or viremia along with computerized tomography nodal or soft-tissue abnormalities consistent with LPD. Patients with EBV viremia>1000 copies on at least two consecutive occasions were treated with rituximab at a dose of 375 mg/m2 weekly until clearance of EBV viremia (usually for a maximum of 4 infusions). @\@"`h:`hO`@G"      n  E   6  ) %@@ } Hd(Y(Y(Y(Y"  h.b  ` 2 %@@ ~ BTT"`41 Results & 0( 2 %%  Hl3333"`" 'Patients' characteristics are summarized in Table 1. In 141 patients (81%), the EBV load remained less than 1000 EBV copies/105 cells at all time, and none of these patients experienced any sign or symptom of EBV-related LPD. The remaining 34 patients (19%) experienced at least one EBV viremia episode. The cumulative incidence of EBV viremia is shown in Figure 1. EBV viremia was observed at a median of 58 (range 0-930) days after allo-HSCT, with 79% (n=27) of reactivations occurring during the first 6 months. The highest viral loads were measured between the 2nd and 12th week after transplantation (Figure 2). Of note, in 17 of the 34 patients who experienced EBV reactivation, the EBV load was elevated only once, and this was not accompanied by any clinical symptom, and normalized spontaneously. (5@`@6 `  h ^ ` @`@ ` $`$(@(5  ?  *   9   %@@I  N w w)A Following allo-HSCT, EBV viremia and EBV-related proliferations are well recognized complications. Established LPD post-allo-HSCT is associated with significant mortality and morbidity. On the other hand, early detection strategies with serial measurement of EBV-DNA load in peripheral blood samples have helped to identify high-risk patients and to diagnose early lymphoproliferation. Moreover, pre-emptive anti-B-cell therapies are increasingly used and have been shown to be successful in preventing LPD. To date, few data has been reported regarding the incidence and features of EBV-related disease following RIC allo-HSCT in adult patients with hematological diseases.The aim of this analysis was to define incidence and potential risk factors predicting the development of EBV reactivation in the first 6 months following RIC allo-HSCT in adult patients, and to assess its impact on clinical outcome.`@` @ ` ;@@  Cj     o@@T  S A)"`4J'0i  H w w#4b E1Most importantly, none of the patients from this series developed EBV-induced LPD. The 17 patients who had EBV DNA levels exceeding 1000 copies/105 cells on 2 or more occasions were pre-emptively treated with a median number of 3 (range, 1-4) rituximab infusions which resulted in complete clearance of EBV viremia in all, but one patient (97%). Only the use of ATG as part of the RIC regimen prior to allo-HSCT was significantly associated with the risk of EBV reactivation (P=0.007). In the Cox multivariate analysis, the use of ATG stayed an idepedent risk factor associated with EBV reactivation (P=0.0027). There was no statistically significant difference in terms of overall survival (OS) between those patients who experienced an EBV reactivation after allo-HSCT and those who did not (p = 0.62, Figure 3). .1(2`h`@` @ '` @`@2 ` $@$A(`(,,0`044c8`8 <<`@` @    0   7   9H  '   2 A  B      @@  HH  w w?$36 8<Figure 2. Median of copies of EBV DNA when EBV reactivation "= 2;            @@2  Hx< w w?$22 @Figure 1. Cumulative incidence of EBV viremia post RIC allo-SCT "A 2?@@@2  H8 w wx`$1$ 4Figure 3. Probability of Survival post RIC allo-SCT .5 23  4@@& F;"   #"F: vww F;"   TQ w w?+ w 17 (6-48)nI   TS w w?+ xEngraftment days (ANC>0.5)nI P  T0d w w?!;" v 34 (6-181)nI? N  Tf w w?! S 114 (65%) 24 (14%) 37 (21%)TTTnI L  Tq w w?+ y 6.1 (0.7-36.7)nIH J  T< w w? \ 77 (44%) 93 (52%) 5 (4%)]]]nI H  T w w? , 134 (77%) 41 (23%)---nI2 F  T w w? F 84 (48%) 80 (46%) 11 (6%)GGGnIE D  Tȏ w w?4 Y 10 (6%) 165 (94%) ZZZnI. B  T| w w?4 B 30 (17%) 145 (83%)CCCnI7 @  T` w w? K 85 (49%) 86 (49%) 4 (2%)LLLnI >  T w w?Y 1 98 (56%) 101 (58%)222nI <  T$ w w?Y x 106 : 69 (61%:39%)nI :  T w w?F y 56 (18-71) nI  T w w?!;" Acute GVHD days after alloSCT"@ nI@  T w w?! *acute GVHD Grade 0-I Grade II Grade III-IVB+@ @+nI&  T w w?+ CD 34+ count/106 kg Bw<@H@nI  T  w w? YImunosupression Cyclosporine (CSA) CSA+mycophenolat-mophetil (MMF) CSA+metothrexate (MTX)XZ#@@@ZnIC  T  w w? -Conditioning with ATG Condtioning without ATGB.  @  @@.nIp  TD  w w? <Donor Matched related Matched unrelated Mismatched unrelated`=@@@=nIL  T(  w w?4 .Stam cell source Bone marrow Peripheral blood J/ @@/nIF  T\  w w?4 6Disease status Standard risk disease High risk disease47@6nIJ  T>  w w? LDiagnosis Myeloid malignancies Lymphoid malignancies Severe aplastic anemia"M C@LnI6  TH  w w?Y 8CMV serostatus Seronegative recipient Seronegative donor"9@58nI   TDS  w w?Y Sex ratio (M:F)" @nI  Tl]  w w?F Patient age (median, range)" @nI`B  01 ?FFZB  s *1 ?ZB  s *1 ?YYZB  s *1 ?ZB  s *1 ?ZB  s *1 ?44ZB  s *1 ?ZB  s *1 ?ZB  s *1 ?ZB  s *1 ?ZB  s *1 ?++ZB  s *1 ?!!`B  01 ?;";"`B  01 ?F;"ZB  s *1 ?F;"`B  01 ?F;"ZB   s *1 ?X $  0A?0$ U  Hg  w wn'# DTable 1. Patients characteristics# 2##@@h  _  T  f fAk5E" 1. Cohen J et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol.2005;129:229-239. 2. Brunstein CG et al. Marked increased risk of Epstein-Barr virus related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108(8):2874-2880. 3. Faye, A et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. BrJ Haematol 2001; 115, 112 118. 4. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21, 1387-1394. b   b   b  :b   $b$ (( ,b, 00 o4b4 88 G?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxy{|}~     $Root EntrydO)PicturesCurrent UserSummaryInformation(8}PowerPoint Document(z֭DocumentSummaryInformation8